As European markets experience a mix of modest gains and losses, with the pan-European STOXX Europe 600 Index rising slightly amid hopes for increased government spending, investors are navigating a landscape marked by trade-related uncertainties and inflation concerns. In this environment, stocks with high insider ownership can offer an appealing level of confidence, as insiders often have unique insights into their companies' potential for growth and resilience against economic headwinds.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Elicera Therapeutics (OM:ELIC) | 27.8% | 97.2% |
| Pharma Mar (BME:PHM) | 11.8% | 40.8% |
| Vow (OB:VOW) | 13.1% | 111.2% |
| Bonesupport Holding (OM:BONEX) | 10.1% | 50.2% |
| Bergen Carbon Solutions (OB:BCS) | 12% | 50.8% |
| Elliptic Laboratories (OB:ELABS) | 22.6% | 88.2% |
| CD Projekt (WSE:CDR) | 29.7% | 40.9% |
| Ortoma (OM:ORT B) | 27.7% | 68.6% |
| Nordic Halibut (OB:NOHAL) | 29.8% | 56.3% |
| Circus (XTRA:CA1) | 26% | 51.4% |
Let's dive into some prime choices out of the screener.
Pharma Mar (BME:PHM)
Simply Wall St Growth Rating: ★★★★★★
Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on researching, developing, producing, and commercializing bio-active principles for oncology across various international markets; it has a market cap of approximately €1.52 billion.
Operations: The company's revenue is primarily derived from its oncology segment, which generated €174.59 million, while its RNA Interference (RNAi) segment contributed €0.26 million.
Insider Ownership: 11.8%
Earnings Growth Forecast: 40.8% p.a.
Pharma Mar exhibits strong growth potential with its earnings forecasted to grow significantly at 40.8% annually, outpacing the Spanish market. Despite a recent decline in sales, net income surged to €26.13 million from €1.14 million year-on-year, indicating high-quality earnings. The company trades at a substantial discount of 47.4% below estimated fair value and maintains a volatile share price but benefits from high insider ownership and anticipated robust revenue growth of 24.2%.
- Click here and access our complete growth analysis report to understand the dynamics of Pharma Mar.
- In light of our recent valuation report, it seems possible that Pharma Mar is trading beyond its estimated value.
BioArctic (OM:BIOA B)
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK15.85 billion.
Operations: The company's revenue is derived from its biotechnology segment, totaling SEK257.35 million.
Insider Ownership: 33.8%
Earnings Growth Forecast: 38.9% p.a.
BioArctic demonstrates promising growth prospects, with revenue expected to grow 31.6% annually, surpassing the Swedish market's rate. The company recently secured a significant agreement with Bristol Myers Squibb, receiving an upfront US$100 million and potential milestones up to US$1.25 billion. Despite recent losses, insider buying indicates confidence in future profitability within three years and a high forecasted return on equity of 37.5%. The stock trades significantly below its estimated fair value.
- Click to explore a detailed breakdown of our findings in BioArctic's earnings growth report.
- The valuation report we've compiled suggests that BioArctic's current price could be quite moderate.
Fabege (OM:FABG)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Fabege AB (publ) is a Swedish property company specializing in the development, investment, and management of commercial premises, with a market cap of SEK25.01 billion.
Operations: The company's revenue segments include Management at SEK3.07 billion, Processing at SEK243 million, Birger Bostad at SEK244 million, and Project at SEK28 million.
Insider Ownership: 16%
Earnings Growth Forecast: 52.8% p.a.
Fabege is poised for profitability within three years, with earnings projected to grow 52.77% annually. Insider confidence is evident through substantial recent purchases, contrasting with no significant sales. Despite a slow revenue growth forecast of 2.1% annually, the company secured key leases in Arenastaden and Stockholm's inner city, enhancing occupancy rates and rental income potential. However, interest coverage remains weak and dividends are not well covered by earnings despite a recent increase to SEK 2 per share for 2024.
- Get an in-depth perspective on Fabege's performance by reading our analyst estimates report here.
- The analysis detailed in our Fabege valuation report hints at an inflated share price compared to its estimated value.
Where To Now?
- Click through to start exploring the rest of the 232 Fast Growing European Companies With High Insider Ownership now.
- Contemplating Other Strategies? The end of cancer? These 21 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Fabege might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com